Raras
Buscar doenças, sintomas, genes...
Adenoma hipofisário funcional
ORPHA:314753DOENÇA RARA

Um tumor benigno na glândula hipófise, que produz hormônios e está associado a um conjunto de problemas causados por esses hormônios.

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

Um tumor benigno na glândula hipófise, que produz hormônios e está associado a um conjunto de problemas causados por esses hormônios.

Pesquisas ativas
1 ensaio
6 total registrados no ClinicalTrials.gov
Publicações científicas
400 artigos
Último publicado: 2026 Apr 6
🏥
SUS: Sem cobertura SUSScore: 0%
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

📏
Crescimento
39 sintomas
🦴
Ossos e articulações
14 sintomas
🧠
Neurológico
13 sintomas
🧬
Pele e cabelo
12 sintomas
👁️
Olhos
9 sintomas
❤️
Coração
9 sintomas

+ 92 sintomas em outras categorias

Características mais comuns

Amenorreia
Bócio
Adenoma de células produtoras de prolactina hipofisárias
Defeito do campo visual
Hemianopsia heterônima
Adenoma de células gonadotróficas hipofisárias
219sintomas
Sem dados (219)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 219 características clínicas mais associadas, ordenadas por frequência.

AmenorreiaAmenorrhea
BócioGoiter
Adenoma de células produtoras de prolactina hipofisáriasPituitary prolactin cell adenoma
Defeito do campo visualVisual field defect
Hemianopsia heterônimaHeteronymous hemianopia

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Total histórico400PubMed
Últimos 10 anos200publicações
Pico202139 papers
Linha do tempo
2026Hoje · 2026🧪 2004Primeiro ensaio clínico📈 2021Ano de pico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

7 genes identificados com associação a esta condição.

CDH23Cadherin-23Candidate gene tested inTolerante
FUNÇÃO

Cadherins are calcium-dependent cell adhesion proteins. They preferentially interact with themselves in a homophilic manner in connecting cells. CDH23 is required for establishing and/or maintaining the proper organization of the stereocilia bundle of hair cells in the cochlea and the vestibule during late embryonic/early postnatal development. It is part of the functional network formed by USH1C, USH1G, CDH23 and MYO7A that mediates mechanotransduction in cochlear hair cells. Required for norma

LOCALIZAÇÃO

Cell membrane

VIAS BIOLÓGICAS (2)
Sensory processing of sound by outer hair cells of the cochleaSensory processing of sound by inner hair cells of the cochlea
MECANISMO DE DOENÇA

Usher syndrome 1D

USH is a genetically heterogeneous condition characterized by the association of retinitis pigmentosa with sensorineural deafness. Age at onset and differences in auditory and vestibular function distinguish Usher syndrome type 1 (USH1), Usher syndrome type 2 (USH2) and Usher syndrome type 3 (USH3). USH1 is characterized by profound congenital sensorineural deafness, absent vestibular function and prepubertal onset of progressive retinitis pigmentosa leading to blindness.

OUTRAS DOENÇAS (12)
autosomal recessive nonsyndromic hearing loss 12Usher syndrome type 1Dnonsyndromic genetic hearing lossUsher syndrome
HGNC:13733UniProt:Q9H251
NR3C1Glucocorticoid receptorCandidate gene tested inAltamente restrito
FUNÇÃO

Receptor for glucocorticoids (GC) (PubMed:27120390, PubMed:37478846). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modulator of other transcription factors (PubMed:28139699). Affects inflammatory responses, cellular proliferation and differentiation in target tissues. Involved in chromatin remodeling (PubMed:9590696). Plays a role in rapid mRNA degradation by binding to the 5' UTR of ta

LOCALIZAÇÃO

CytoplasmNucleusMitochondrionCytoplasm, cytoskeleton, spindleCytoplasm, cytoskeleton, microtubule organizing center, centrosomeChromosomeNucleus, nucleoplasm

VIAS BIOLÓGICAS (6)
PTK6 ExpressionRegulation of RUNX2 expression and activityRegulation of NPAS4 gene transcriptionFOXO-mediated transcription of oxidative stress, metabolic and neuronal genesSUMOylation of intracellular receptors
MECANISMO DE DOENÇA

Glucocorticoid resistance, generalized

An autosomal dominant disease characterized by increased plasma cortisol concentration and high urinary free cortisol, resistance to adrenal suppression by dexamethasone, and the absence of Cushing syndrome typical signs. Clinical features include hypoglycemia, hypertension, metabolic alkalosis, chronic fatigue and profound anxiety.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
55.3 TPM
Nervo tibial
34.5 TPM
Tecido adiposo
34.1 TPM
Fibroblastos
33.6 TPM
Artéria tibial
32.7 TPM
OUTRAS DOENÇAS (2)
glucocorticoid resistanceCushing disease due to pituitary adenoma
HGNC:7978UniProt:P04150
ATRXTranscriptional regulator ATRXCandidate gene tested inAltamente restrito
FUNÇÃO

Involved in transcriptional regulation and chromatin remodeling. Facilitates DNA replication in multiple cellular environments and is required for efficient replication of a subset of genomic loci. Binds to DNA tandem repeat sequences in both telomeres and euchromatin and in vitro binds DNA quadruplex structures. May help stabilizing G-rich regions into regular chromatin structures by remodeling G4 DNA and incorporating H3.3-containing nucleosomes. Catalytic component of the chromatin remodeling

LOCALIZAÇÃO

NucleusChromosome, telomereNucleus, PML body

VIAS BIOLÓGICAS (2)
Inhibition of DNA recombination at telomereDefective Inhibition of DNA Recombination at Telomere Due to DAXX Mutations
MECANISMO DE DOENÇA

Alpha-thalassemia/impaired intellectual development syndrome, X-linked

A disorder characterized by severe psychomotor retardation, facial dysmorphism, urogenital abnormalities, and alpha-thalassemia. An essential phenotypic trait are hemoglobin H erythrocyte inclusions.

OUTRAS DOENÇAS (5)
intellectual disability-hypotonic facies syndrome, X-linked, 1alpha-thalassemia-myelodysplastic syndromealpha thalassemia-X-linked intellectual disability syndromegastric neuroendocrine neoplasm
HGNC:886UniProt:P46100
BRAFSerine/threonine-protein kinase B-rafCandidate gene tested inAltamente restrito
FUNÇÃO

Protein kinase involved in the transduction of mitogenic signals from the cell membrane to the nucleus (Probable). Phosphorylates MAP2K1, and thereby activates the MAP kinase signal transduction pathway (PubMed:21441910, PubMed:29433126). Phosphorylates PFKFB2 (PubMed:36402789). May play a role in the postsynaptic responses of hippocampal neurons (PubMed:1508179)

LOCALIZAÇÃO

NucleusCytoplasmCell membrane

VIAS BIOLÓGICAS (4)
Spry regulation of FGF signalingParadoxical activation of RAF signaling by kinase inactive BRAFARMS-mediated activationSignalling to p38 via RIT and RIN
OUTRAS DOENÇAS (18)
Noonan syndrome 7LEOPARD syndrome 3melanoma, cutaneous malignant, susceptibility to, 1lung cancer
HGNC:1097UniProt:P15056
USP48Ubiquitin carboxyl-terminal hydrolase 48Candidate gene tested inAltamente restrito
FUNÇÃO

Deubiquitinase that recognizes and hydrolyzes the peptide bond at the C-terminal Gly of ubiquitin. Involved in the processing of polyubiquitin precursors as well as that of ubiquitinated proteins (PubMed:16214042, PubMed:34059922). Plays a role in the regulation of NF-kappa-B activation by TNF receptor superfamily via its interactions with RELA and TRAF2. May also play a regulatory role at postsynaptic sites. Plays an important role in cell cycle progression by deubiquitinating Aurora B/AURKB an

LOCALIZAÇÃO

CytoplasmNucleusCell projection, cilium

VIAS BIOLÓGICAS (1)
Ub-specific processing proteases
MECANISMO DE DOENÇA

Deafness, autosomal dominant, 85

A form of non-syndromic, sensorineural hearing loss. Sensorineural hearing loss results from damage to the neural receptors of the inner ear, the nerve pathways to the brain, or the area of the brain that receives sound information. DFNA85 is characterized by progressive hearing loss, with onset in childhood or young adulthood.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
68.8 TPM
Cérebro - Hemisfério cerebelar
55.8 TPM
Cerebelo
55.3 TPM
Ovário
36.8 TPM
Glândula adrenal
35.5 TPM
OUTRAS DOENÇAS (3)
hearing loss, autosomal dominant 85autosomal dominant nonsyndromic hearing lossCushing disease due to pituitary adenoma
HGNC:18533UniProt:Q86UV5
TP53Cellular tumor antigen p53Candidate gene tested inAltamente restrito
FUNÇÃO

Multifunctional transcription factor that induces cell cycle arrest, DNA repair or apoptosis upon binding to its target DNA sequence (PubMed:11025664, PubMed:12524540, PubMed:12810724, PubMed:15186775, PubMed:15340061, PubMed:17317671, PubMed:17349958, PubMed:19556538, PubMed:20673990, PubMed:20959462, PubMed:22726440, PubMed:24051492, PubMed:24652652, PubMed:35618207, PubMed:36634798, PubMed:38653238, PubMed:9840937). Acts as a tumor suppressor in many tumor types; induces growth arrest or apop

LOCALIZAÇÃO

CytoplasmNucleusNucleus, PML bodyEndoplasmic reticulumMitochondrion matrixCytoplasm, cytoskeleton, microtubule organizing center, centrosome

VIAS BIOLÓGICAS (10)
TP53 Regulates Metabolic GenesRegulation of TP53 ExpressionRegulation of TP53 DegradationOncogene Induced SenescenceOxidative Stress Induced Senescence
EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
73.0 TPM
Skin Sun Exposed Lower leg
37.0 TPM
Skin Not Sun Exposed Suprapubic
35.2 TPM
Fibroblastos
32.9 TPM
Ovário
32.4 TPM
OUTRAS DOENÇAS (29)
Li-Fraumeni syndromenasopharyngeal carcinoma, susceptibility to, 1hepatocellular carcinomafamilial pancreatic carcinoma
HGNC:11998UniProt:P04637
USP8Ubiquitin carboxyl-terminal hydrolase 8Disease-causing germline mutation(s) inAltamente restrito
FUNÇÃO

Hydrolase that can remove conjugated ubiquitin from proteins and therefore plays an important regulatory role at the level of protein turnover by preventing degradation. Converts both 'Lys-48' an 'Lys-63'-linked ubiquitin chains. Catalytic activity is enhanced in the M phase. Involved in cell proliferation. Required to enter into S phase in response to serum stimulation. May regulate T-cell anergy mediated by RNF128 via the formation of a complex containing RNF128 and OTUB1. Probably regulates t

LOCALIZAÇÃO

CytoplasmNucleusEndosome membraneCell membrane

VIAS BIOLÓGICAS (4)
Downregulation of ERBB2:ERBB3 signalingRegulation of FZD by ubiquitinationNegative regulation of MET activityUb-specific processing proteases
MECANISMO DE DOENÇA

Pituitary adenoma 4, ACTH-secreting

A form of pituitary adenoma, a neoplasm of the pituitary gland and one of the most common neuroendocrine tumors. Pituitary adenomas are clinically classified as functional and non-functional tumors, and manifest with a variety of features, including local invasion of surrounding structures and excessive hormone secretion. Functional pituitary adenomas are further classified by the type of hormone they secrete. PITA4 results in excessive production of adrenocorticotropic hormone. This leads to hypersecretion of cortisol by the adrenal glands and ACTH-dependent Cushing syndrome. Clinical manifestations of Cushing syndrome include facial and truncal obesity, abdominal striae, muscular weakness, osteoporosis, arterial hypertension, diabetes.

EXPRESSÃO TECIDUAL(Ubíquo)
Fibroblastos
10.4 TPM
Linfócitos
9.2 TPM
Nervo tibial
9.1 TPM
Cervix Endocervix
8.7 TPM
Ovário
8.3 TPM
OUTRAS DOENÇAS (2)
Cushing disease due to pituitary adenomaautosomal recessive spastic paraplegia type 59
HGNC:12631UniProt:P40818

Variantes genéticas (ClinVar)

3,975 variantes patogênicas registradas no ClinVar.

🧬 CDH23: NM_022124.6(CDH23):c.5629G>A (p.Asp1877Asn) ()
🧬 CDH23: NM_022124.6(CDH23):c.9949G>A (p.Ala3317Thr) ()
🧬 CDH23: NM_022124.6(CDH23):c.1526del (p.Asp509fs) ()
🧬 CDH23: NM_022124.6(CDH23):c.3396C>T (p.Gly1132=) ()
🧬 CDH23: NM_022124.6(CDH23):c.1624G>T (p.Glu542Ter) ()
Ver todas no ClinVar

Vias biológicas (Reactome)

62 vias biológicas associadas aos genes desta condição.

Sensory processing of sound by inner hair cells of the cochlea Sensory processing of sound by outer hair cells of the cochlea HSP90 chaperone cycle for steroid hormone receptors (SHR) in the presence of ligand Nuclear Receptor transcription pathway SUMOylation of intracellular receptors PTK6 Expression Regulation of RUNX2 expression and activity FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes Potential therapeutics for SARS Regulation of NPAS4 gene transcription Inhibition of DNA recombination at telomere Defective Inhibition of DNA Recombination at Telomere Due to DAXX Mutations Defective Inhibition of DNA Recombination at Telomere Due to ATRX Mutations Spry regulation of FGF signaling Frs2-mediated activation ARMS-mediated activation Signalling to p38 via RIT and RIN RAF activation MAP2K and MAPK activation Negative feedback regulation of MAPK pathway Negative regulation of MAPK pathway Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF1 fusions Paradoxical activation of RAF signaling by kinase inactive BRAF Signaling downstream of RAS mutants Signaling by RAF1 mutants SHOC2 M1731 mutant abolishes MRAS complex function Gain-of-function MRAS complexes activate RAF signaling Ub-specific processing proteases Activation of NOXA and translocation to mitochondria Activation of PUMA and translocation to mitochondria Pre-NOTCH Transcription and Translation Oxidative Stress Induced Senescence Formation of Senescence-Associated Heterochromatin Foci (SAHF) Oncogene Induced Senescence DNA Damage/Telomere Stress Induced Senescence SUMOylation of transcription factors Autodegradation of the E3 ubiquitin ligase COP1 Association of TriC/CCT with target proteins during biosynthesis Pyroptosis TP53 Regulates Metabolic Genes Ovarian tumor domain proteases Recruitment and ATM-mediated phosphorylation of repair and signaling proteins at DNA double strand breaks Interleukin-4 and Interleukin-13 signaling TP53 Regulates Transcription of DNA Repair Genes TP53 Regulates Transcription of Genes Involved in Cytochrome C Release TP53 regulates transcription of several additional cell death genes whose specific roles in p53-dependent apoptosis remain uncertain TP53 Regulates Transcription of Caspase Activators and Caspases TP53 Regulates Transcription of Death Receptors and Ligands TP53 Regulates Transcription of Genes Involved in G2 Cell Cycle Arrest TP53 regulates transcription of additional cell cycle genes whose exact role in the p53 pathway remain uncertain TP53 Regulates Transcription of Genes Involved in G1 Cell Cycle Arrest Regulation of TP53 Expression Regulation of TP53 Activity through Phosphorylation Regulation of TP53 Degradation Regulation of TP53 Activity through Acetylation Regulation of TP53 Activity through Association with Co-factors Regulation of TP53 Activity through Methylation Downregulation of ERBB2:ERBB3 signaling Regulation of FZD by ubiquitination Negative regulation of MET activity

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
2Fase 23
·Pré-clínico2
Medicamentos catalogadosEnsaios clínicos· 0 medicamentos · 5 ensaios
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Adenoma hipofisário funcional

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

🟢 Recrutando agora

1 pesquisa recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

Outros ensaios clínicos

6 ensaios clínicos encontrados, 1 ativos.

Distribuição por fase
Ver todos no ClinicalTrials.gov
🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
260 papers (10 anos)
#1

The clinical value of [18F]-fluoro-ethyl-L-tyrosine PET ([18F]FET-PET) correlated with MRI in patients with functioning pituitary adenomas: an observational cohort study.

Pituitary2026 Mar 07

To assess the clinical value of [18F]fluoroethyl-L-tyrosine PET ([18F]FET-PET) correlated with MRI in patients with functioning pituitary adenoma (FPA) with negative or equivocal conventional MRIs during diagnosis, persistent disease and recurrence. Retrospective observational cohort study of 34 patients with FPAs who underwent a total of 37 [18F]FET-PETs (Cushing’s disease: n = 19, acromegaly: n = 14, prolactinoma: n = 3, and TSH producing adenoma: n = 1) between January 2022 and April 2025. The clinical performance was assessed in the surgically treated cohort, using confirmative histopathology and/or postoperative remission as reference standard. [18F]FET-PET identified a single lesion in 28 scans (76%), two lesions in 1 scan (3%), and no lesion in 8 scans (22%). [18F]FET-PET and MRI were concordant positive in 14/37 scans, concordant negative in 1/37, discordant MRI+/[18F]FET-PET + different location in 2/37, discordant MRI-/[18F]FET-PET + in 8/37, discordant MRI+/[18F]FET-PET- in 7/37 and partly concordant in 5/37 scans. In 14 cases surgery resulted in confirmative histopathology and/or postoperative remission, 12 of those had a positive [18F]FET-PET. In 6 cases surgery did not result in confirmative histopathology and/or postoperative remission, of whom 5 had a positive [18F]FET-PET. Overall, the sensitivity was 86% and the positive predictive value 71%. In three patients with acromegaly, [18F]FET-PET was able to localize a lesion, despite biochemical control under continued somatostatin analogue treatment. [18F]FET-PET enhances lesion detection and improves personalized treatment in patients with FPA and negative or equivocal conventional MRIs throughout the disease course. Consensus on the timing of [18F]FET-PET with respect to medication and biochemical status is warranted. The online version contains supplementary material available at 10.1007/s11102-025-01634-w.

#2

Oridonin regulates pituitary-derived folliculostellate cells apoptosis via the p38 MAPK/p53 signalling pathway.

European journal of pharmacology2026 Mar 28

Treatment of non-functioning pituitary adenoma remains challenging owing to a lack of effective pharmacological therapies. A previous study has shown that oridonin (ORI) induces apoptosis in pituitary-derived folliculostellate (PDFS) cells; therefore, this study further investigated the molecular mechanisms by which ORI-mediated regulates apoptosis in PDFS cells. To confirm the regulatory role of the p38 mitogen-activated protein kinase (MAPK)/p53 signalling pathway, molecular docking and the p38 MAPK inhibitor SB202190 were used to evaluate pathway modulation. Effects on cell viability, migration, invasion, and apoptosis were evaluated using Calcein-AM/Propidium Iodide (PI) double staining, Transwell migration and invasion assays, and Western blot analysis. To further assess the in vivo effects of ORI, a subcutaneous xenograft model in nude mice was established, and ORI was administered at 5 and 10 mg/kg to assess therapeutic efficacy and safety. Safety was evaluated by analysing histopathological changes in major organs using haematoxylin-eosin (H&E) staining. Western blot analysis of tumour tissues was conducted to assess activation of the p38 MAPK/p53 pathway and the expression of apoptosis-related proteins. Molecular docking and Western blot assays confirmed that ORI binds to p38 protein with an affinity of -7.3 kcal/mol, markedly increasing p38 phosphorylation and p53 expression. The p38 MAPK inhibitor SB202190 reversed ORI-induced effects on cell death, cell migration and invasion, and apoptosis, highlighting the critical role of the p38 MAPK/p53 pathway. ORI effectively suppressed subcutaneous tumour growth in nude mice without notable toxicity while upregulating apoptosis-related proteins Bax and cleaved caspase-3 and downregulating Bcl-2 through activation of the p38 MAPK/p53 pathway.

#3

Sex-related differences in healthcare utilization and costs among patients with pituitary adenomas.

Pituitary2026 Feb 07

To systematically summarize and evaluate the current evidence regarding sex-based differences in healthcare utilization (HCRU), direct costs, and indirect socioeconomic burden in patients with pituitary adenomas. A systematic literature search of PubMed, EMBASE, and Web of Science identified studies reporting HCRU and/or cost data with sex-stratified analyses. Studies focusing on drug-specific cost-effectiveness, case reports, and scenario-based models were excluded. Eight studies met the inclusion criteria, including non-functioning pituitary adenoma, prolactinoma, acromegaly, Cushing's disease (CD), and perioperative pituitary tumor cohorts from Europe and the United States. Findings were synthesized narratively due to methodological heterogeneity and the scarcity of sex-specific cost estimates. Total and surgical costs did not differ between men and women across most settings in Europe. Only one U.S. acromegaly cohort showed lower adjusted annual costs in women, and one Chinese perioperative patient cohort reported lower inpatient charges among women. In contrast, sex-based differences in HCRU were consistent and clinically relevant: women with acromegaly demonstrated longer diagnostic delays, more pre-diagnostic visits, higher specialist engagement, and more treatment modifications. Perioperatively, sex was not a predictor of length of stay or cost, but several cohorts reported higher rates of cerebrospinal fluid leak, arginine-vasopressin deficiency, and late hyponatremia in women. The most pronounced disparity was observed in indirect socioeconomic burden, with women more frequently experiencing reduced work capacity, early retirement, psychosocial distress, and poorer quality-of-life in acromegaly and CD. Although sex-based differences in overall healthcare costs are limited, women face a disproportionately complex and burdensome care trajectory. Standardized, value-based care pathways may help mitigate these disparities, underscoring the need for prospective, sex-stratified studies.

#4

Decoy Lesion in Functional Multiple Pituitary Adenomas: Literature Review and Illustrative Cases on Diagnostic Pitfalls and Surgical Strategies.

World neurosurgery2026 Mar

Multiple pituitary adenomas (MPA), particularly those involving functioning adenoma, represent a special subtype of pituitary adenomas that pose dual challenges in diagnosis and treatment. In this setting, the coexistence of hormonally active and silent lesions may result in a diagnostic pitfall when a radiologically dominant tumor does not correspond to the hormonally responsible lesion. This misleading lesion, often referred to as decoy lesion, can adversely influence surgical decision-making in patients with MPA. We systematically reviewed English-language case reports of multiple pituitary adenomas published between 2000 and 2024 in PubMed, Web of Science, and Embase and present 2 illustrative cases. Lesions were classified as responsibility lesions or decoy lesions based on an operational definition incorporating endocrine outcomes, radiological features, and surgical findings. A total of 35 patients from 24 case reports met the inclusion criteria. The mean age was 40 years, with 12 male and 23 female patients. The most common clinical manifestations were acromegaly (n = 13, 37%) and Cushing's syndrome (n = 11, 31%). Our findings indicate that, compared with decoy lesions, responsibility lesions are less conspicuous on preoperative MRI and usually smaller in size. Overall, 43% of these patients (15/35) did not achieve biochemical remission after the initial surgery, with missed identification of the responsibility lesion reported in a substantial proportion of cases. Identifying decoy lesion and distinguishing it from responsibility lesion may improve surgical planning and endocrine outcomes in complex MPA cases.

#5

Cavernous Sinus Medial Wall Resection: A Retrospective Single-Institution Study on Outcomes in Functional Pituitary Adenomas.

Operative neurosurgery (Hagerstown, Md.)2026 Feb 04

Surgery remains first-line therapy for most functioning pituitary adenomas (FPA). Remission rates are lower in some patients due to cavernous sinus invasion. Medial wall resection (MWR) may improve biochemical remission but remains largely underutilized. Our objective is to assess outcomes of MWR in patients with FPA at Oregon Health & Science University performed by a single neurosurgeon. Retrospective, Institutional Review Board-approved study: patients ≥18 years, FPA after MWR with ≥ 3-months follow-up. Remission: normal prolactin, insulin-like growth factor-1, and either adrenal insufficiency or normal cortisol at 3 months for prolactinoma, acromegaly and Cushing disease (CD), respectively. Arginine vasopressin deficiency (AVP-D) defined as needing desmopressin at the last follow-up. Logistic regression identified predictors of biochemical remission. Sixty-four patients, mean age 41.2 years and adenoma size 12.6 mm; CD (39.1%), prolactinoma (37.5%), acromegaly (23.4%). Knosp grade 0 (31.2%), 1 (32.81%), 3 (14%) and 4 (12.5%). Overall remission rate was 82.8%, CD (92%), prolactinoma (87.5%), and acromegaly (60%). Acromegaly (odd ratio 0.035, 95% CI [0.0034, 0.345], P = .004) compared with CD and tumor size (odd ratio 0.87 per mm increase, 95% CI 0.79-0.96, P = .007) were negative predictors of remission. The mean operative time showed significant increase in Crooke (357 ± 128 minutes) vs non-Crooke corticotroph (243 ± 39.7 minutes, P = .012, 95% CI [14.9, 213]), lactotroph (243.1 ± 65.1 minutes, P = .009, 95% CI [17.2, 210.5]), or somatotroph (232.5 ± 45.8 minutes, P = .031, 95% CI [5.9, 243.1]) tumors. Complications include new hypopituitarism (9.4%): adrenal insufficiency 12.8% (prolactinoma and acromegaly), hypothyroidism (1.5%), hypogonadism (1.5%); arginine vasopressin deficiency (20.3%), and transient syndrome of inappropriate antidiuretic hormone (4.7%), 1 cerebrospinal fluid leak and carotid injury (1.5%) repaired with direct coagulation without neurological sequelae. MWR is safe and effective for the surgical management of FPA, particularly in CD and prolactinomas. Despite a steep learning curve, the high remission rates, and low complications support its use in well-selected patients by experienced multidisciplinary teams.

Publicações recentes

Ver todas no PubMed

📚 EuropePMC150 artigos no totalmostrando 197

2026

The clinical value of [18F]-fluoro-ethyl-L-tyrosine PET ([18F]FET-PET) correlated with MRI in patients with functioning pituitary adenomas: an observational cohort study.

Pituitary
2026

Oridonin regulates pituitary-derived folliculostellate cells apoptosis via the p38 MAPK/p53 signalling pathway.

European journal of pharmacology
2026

Sex-related differences in healthcare utilization and costs among patients with pituitary adenomas.

Pituitary
2026

Decoy Lesion in Functional Multiple Pituitary Adenomas: Literature Review and Illustrative Cases on Diagnostic Pitfalls and Surgical Strategies.

World neurosurgery
2026

Impact of sex on mortality in patients with pituitary adenomas.

Pituitary
2026

Cavernous Sinus Medial Wall Resection: A Retrospective Single-Institution Study on Outcomes in Functional Pituitary Adenomas.

Operative neurosurgery (Hagerstown, Md.)
2026

Sex and Age Differences in Transcription Factor and Hormonal Immunostaining in Patients With Nonfunctioning Pituitary Adenomas.

Operative neurosurgery (Hagerstown, Md.)
2026

Clinicopathological features and outcomes in non-functioning pituitary neuroendocrine tumors: a transcription factor-driven subtype analysis.

Journal of neuro-oncology
2025

Clinical, radiological, and pathological characteristics and long-term outcomes of silent corticotroph adenomas: a retrospective study.

BMC endocrine disorders
2025

[Refractory pituitary prolactinoma:current treatment status and challenges].

Zhonghua yi xue za zhi
2025

Managing Atopic Dermatitis with Dupilumab in Special Populations: A Case Series Study.

Clinical, cosmetic and investigational dermatology
2025

Intensity-Modulated Proton Therapy for an Unresectable Giant Non-functioning Pituitary Adenoma: A Case Report and Literature Review.

Cureus
2025

Neurocognitive evaluation of patients with non-functioning pituitary adenoma.

Pituitary
2025

The association between sleep quality and cognitive function in patients with non-functioning pituitary adenoma.

Endocrine connections
2025

Autoimmune thyroid disease and pituitary adenoma in a female patient with 18p deletion syndrome: a case report and review of the literature.

BMC endocrine disorders
2025

Isolated syndrome of inappropriate antidiuresis (SIAD) after Transphenoidal surgery of a non-functioning pituitary adenoma: clinical case report.

Oxford medical case reports
2025

Congress of Neurological Surgeons Systematic Review and Evidence-Based Guidelines for the Role of Imaging for Patients With Functioning Pituitary Adenomas.

Neurosurgery
2025

Congress of Neurological Surgeons Systematic Review and Evidence-Based Guidelines for the Role of Radiosurgery for Patients With Functioning Pituitary Adenomas.

Neurosurgery
2025

Anemia in Patients With Pituitary Adenomas: Prevalence and Correlation With Hypopituitarism.

Cureus
2025

Venous thromboembolism in patients with pituitary adenoma: UK multicentre cohort study.

European journal of endocrinology
2025

EEA for sellar chodrosarcomas: case series with literature review.

Chinese neurosurgical journal
2025

Baseline testosterone levels as a predictor of hypogonadism resolution in male patients with isolated hyperprolactinemia.

Pituitary
2025

PANOMEN-3 grading score is reliable in predicting pituitary adenoma behavior and prognosis: a single center cohort study.

Endocrine
2025

Headache as an indication for surgery in non-functioning pituitary adenoma and Rathke's cleft cyst: A systematic review.

Clinical neurology and neurosurgery
2025

Soluble alpha klotho-impact of biological variables and reference intervals for adults.

European journal of endocrinology
2025

Cognitive function and fatigue before and after transsphenoidal surgery in patients with pituitary adenoma: a prospective study.

Pituitary
2025

Conservatively managed non-functioning pituitary macroadenomas-cohort study from the UK Non-functioning Pituitary Adenoma Consortium.

European journal of endocrinology
2025

Metformin induces apoptosis in pituitary-derived folliculostellate cells via the IL-6/ERK pathway.

Discover oncology
2025

Impulse control disorders in patients with pituitary adenoma managed with or without dopamine agonists: a cross-sectional study from a UK centre.

Pituitary
2025

Incidental High-Grade Sellar Solitary Fibrous Tumor Mimicking Non-Functioning Pituitary Adenoma: A Case Report and Literature Review.

The American journal of case reports
2025

Coexisting Non-functioning Pituitary Macroadenoma and Sellar-Suprasellar Lipoma: A Case Report and Literature Review.

Acta medica Philippina
2025

Etiology, presentation, and outcomes of hyperprolactinemia due to pituitary masses in children and adolescents.

Endocrine
2025

Person-centered support for patients with a pituitary tumor following surgery.

Endocrine connections
2024

Knosp and revised Knosp classifications predict non-functioning pituitary adenoma outcomes: a single tertiary center experience.

Journal of medicine and life
2024

A case of non-functioning pituitary adenoma with calcification.

Asian journal of surgery
2024

Quality of life in non-functioning pituitary adenoma: A systematic review.

Neurosurgical review
2025

Cognitive decline in Cushing's syndrome: A systematic review.

Journal of neuroendocrinology
2025

Comparative mortality in pituitary adenomas subtypes: a tertiary referral center study.

Endocrine
2024

Brain Arteriovenous Malformation Hemorrhage and Pituitary Adenoma in a COVID-19-Positive Patient.

Cureus
2024

Phenotypic presentation of MEN1 c.758delC (p.Ser253Cysfs *28) pathogenic variant: a case report.

Oxford medical case reports
2024

SZ-685C inhibits the growth of non-functioning pituitary adenoma by down-regulating miR-340-3p and inducing autophagy.

Heliyon
2024

Pituitary apoplexy: a comprehensive analysis of 93 cases across functioning and non-functioning pituitary adenomas from a single-center.

Pituitary
2024

Lanreotide versus placebo for tumour reduction in patients with a 68Ga-DOTATATE PET-positive, clinically non-functioning pituitary macroadenoma (GALANT study): a randomised, multicentre, phase 3 trial with blinded outcome assessment.

The Lancet regional health. Europe
2025

American Association of Neurological Surgeons/Congress of the Neurological Surgeons Section on Tumors Guidelines: Assessing Their Impact on Brain Tumor Clinical Practice.

Neurosurgery
2024

Differential expression of cancer-related lncRNAs in different subtypes of pituitary adenomas.

Pathology, research and practice
2024

Stem cell-associated transcription factors in non-functioning pituitary neuroendocrine tumours.

Free neuropathology
2024

Cardiovascular risk in patients with acromegaly vs. non-functioning pituitary adenoma following pituitary surgery: an active-comparator cohort study.

Pituitary
2024

High prevalence of morphometric vertebral fractures opportunistically detected on thoracic radiograms in patients with non-functioning pituitary adenoma.

Pituitary
2024

Giant Clinically Non-Functioning Pituitary Adenoma Presenting as New Onset Generalized Tonic‒Clonic Seizures: A Case Report.

International medical case reports journal
2024

Magnetic Resonance Imaging Features of the Sphenoid Sinus in Patients with Non-Functioning Pituitary Adenoma.

Medicina (Kaunas, Lithuania)
2024

Headache in patients with non-functioning pituitary adenoma before and after transsphenoidal surgery - a prospective study.

Pituitary
2024

Clinical and radiographic characteristics of patients with non-functioning pituitary adenomas categorized according to their serum prolactin concentration: novel predictors of postoperative transient diabetes insipidus following surgery.

Endocrine
2024

Medical and Surgical Approaches for a Non-functioning Pituitary Adenoma During Pregnancy.

Cureus
2024

Excess mortality in patients with non-functioning pituitary adenoma: a systematic review and meta-analysis.

Journal of endocrinological investigation
2024

Endoscopic Endonasal Trans-Sphenoidal Minimally Invasive Pituitary Surgery with Image Guided Navigation System (Igns): Learning Experience of Ent Surgeon: First Author.

Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India
2024

Unique case of lymphocytic hypophysitis with normal pituitary hormone serology mimicking a non-functioning pituitary adenoma.

BMC endocrine disorders
2024

Surveillance Imaging Strategies for Pituitary Adenomas: When, How Frequent, and When to Stop.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
2024

Perioperative growth hormone levels as an early predictor of new-onset secondary adrenal insufficiency following transsphenoidal pituitary tumor resection.

Asian journal of surgery
2023

The correlation among Claudin-9, Tyrosine kinase-2, and Signal transducers and activators of transcription-3 expressions in non-functioning pituitary adenoma and invasiveness.

Neuro endocrinology letters
2024

Cabergoline treatment for surgery-naïve non-functioning pituitary macroadenomas.

Pituitary
2023

Visual acuity in patients with non-functioning pituitary adenoma: Prognostic factors and long-term outcome after surgery.

Brain & spine
2023

Skull Base Collision Tumors: Giant Non-functioning Pituitary Adenoma and Olfactory Groove Meningioma.

Cureus
2025

Results of surgical therapy of functioning pituitary adenomas.

Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia
2023

Non-functioning pituitary macroadenoma following surgery: long-term outcomes and development of an optimal follow-up strategy.

Frontiers in surgery
2023

Exploring endocrinological pitfalls in pituitary surgery in the elderly.

Heliyon
2023

Pituitary metastasis of hepatocellular carcinoma as the initial presentations: a case report and review of the literature.

Frontiers in oncology
2023

Pituitary function at presentation and following therapy in patients with non-functional pituitary macroadenomas: a single centre retrospective cohort study.

Endocrine
2023

Natural history of non-functioning pituitary microadenomas: results from the UK non-functioning pituitary adenoma consortium.

European journal of endocrinology
2023

Post-Operative Medium- and Long-Term Endocrine Outcomes in Patients with Non-Functioning Pituitary Adenomas-Machine Learning Analysis.

Cancers
2023

Expression of LINC00174 in different cancers: Review of the literature and bioinformatics analyses.

Pathology, research and practice
2023

Natural history of pituitary apoplexy: a long-term follow-up study.

Postgraduate medical journal
2023

Dysregulation of PVT1 and NEAT1 lncRNAs in pituitary adenomas.

Pathology, research and practice
2023

Sleep quality in patients with non-functioning pituitary adenoma: impact of replacement therapies with an emphasis on the time of hydrocortisone.

Pituitary
2023

Healthcare cost and survival in patients with non-functioning pituitary adenoma.

European journal of endocrinology
2023

Upregulation of MAPKAPK5-AS1, PXN-AS1 and URB1-AS1 lncRNAs in non-functioning pituitary adenoma.

Journal of cellular and molecular medicine
2025

Psychiatric disorders and anger in patients with controlled acromegaly.

Minerva endocrinology
2023

Low Bone Density and High Sclerostin in Non-Functioning Pituitary Adenoma.

Journal of clinical densitometry : the official journal of the International Society for Clinical Densitometry
2023

Evaluation of preoperative visual pathway impairment in patients with non-functioning pituitary adenoma using diffusion tensor imaging coupled with optical coherence tomography.

Frontiers in neuroscience
2022

Collision of Two Tumors: A Case Report of a Lung Adenocarcinoma With Metastasis to a Pituitary Adenoma.

Journal of the ASEAN Federation of Endocrine Societies
2022

Risk Factors, Radiological and Clinical Outcomes in Subclinical and Clinical Pituitary Apoplexy.

Journal of clinical medicine
2022

Changes in Sinonasal and Overall Quality of Life Following Endoscopic Endonasal Surgery for Non-functioning Pituitary Adenomas: Results of A Prospective Observational Study.

Neurology India
2022

Sleep patterns in patients treated for non-secreting intra- and parasellar tumors: A self-report case-control study.

Frontiers in endocrinology
2023

Post-operative surveillance for somatotroph, lactotroph and non-functional pituitary adenomas after curative resection: a systematic review.

Pituitary
2022

Effect of cabergoline on tumor remnant after surgery in nonfunctioning pituitary adenoma.

Journal of neuro-oncology
2023

Epigenomic and transcriptomic landscaping unraveled candidate repositioned therapeutics for non-functioning pituitary neuroendocrine tumors.

Journal of endocrinological investigation
2022

Impact of histopathological classification of non-functioning adenomas on long term outcomes: comparison of the 2004 and 2017 WHO classifications.

Pituitary
2023

Correlation between tumor volume and serum prolactin and its effect on surgical outcomes in a cohort of 219 prolactinoma patients.

Journal of neurosurgery
2022

Management after initial surgery of nonfunctioning pituitary adenoma: surveillance, radiotherapy or surgery?

Radiation oncology (London, England)
2022

DNA Methylation Profiling in Rare Sellar Tumors.

Biomedicines
2022

A Factorial Analysis on Visual Outcomes of Transsphenoidal Surgery for Pituitary Macroadenoma.

Asian journal of neurosurgery
2022

Expression pattern of non-coding RNAs in non-functioning pituitary adenoma.

Frontiers in oncology
2022

Endoscopic transsphenoidal surgery for non-functioning pituitary adenoma: Learning curve and surgical results in a prospective series during initial experience.

Frontiers in surgery
2022

Treatment of non-functioning pituitary adenoma with cabergoline: a systematic review and meta-analysis.

Pituitary
2022

A systematic review of molecular alterations in invasive non-functioning pituitary adenoma.

Endocrine
2022

Sevoflurane anesthesia rather than propofol anesthesia is associated with 3-month postoperative hypocortisolism in patients undergoing endoscopic transsphenoidal surgery for non-functional pituitary adenoma with preoperative normal hypothalamic-pituitary-adrenal axis.

Acta neurochirurgica
2022

Association between overweight and growth hormone secretion in patients with non-functioning pituitary tumors.

PloS one
2022

Discrimination between non-functioning pituitary adenomas and hypophysitis using machine learning methods based on magnetic resonance imaging‑derived texture features.

Pituitary
2022

Ectopic Cushing's syndrome from an ACTH-producing pheochromocytoma with a non-functioning pituitary adenoma.

Endocrinology, diabetes & metabolism case reports
2022

Multivariable Diagnostic Prediction Model to Detect Hormone Secretion Profile From T2W MRI Radiomics with Artificial Neural Networks in Pituitary Adenomas.

Medeniyet medical journal
2022

Late onset of pituitary apoplexy following gonadotropin-releasing hormone agonist for prostate cancer treatment.

BMJ case reports
2022

Determinants of Short-Term Weight Gain Following Surgical Treatment for Craniopharyngioma in Adults.

Journal of Korean Neurosurgical Society
2022

Role of microRNAs in non-functioning pituitary adenoma.

JPMA. The Journal of the Pakistan Medical Association
2021

Metachronous Double Pituitary Adenoma with Altered Transcriptional Factor Profile: A Case Report and Literature Review.

NMC case report journal
2021

Hemostasis through Extended Transsphenoidal Route for Subarachnoid Hemorrhage after Conventional Transsphenoidal Surgery for a Pituitary Adenoma.

NMC case report journal
2022

Gamma knife radiosurgery in pituitary adenomas. A single-center experience.

Medicina
2021

A rare case of macroprolactinoma in a patient with Mayer-Rokitansky-Kuster-Hauser (MRKH) syndrome.

Endocrinology, diabetes & metabolism case reports
2021

An Update on Silent Corticotroph Adenomas: Diagnosis, Mechanisms, Clinical Features, and Management.

Cancers
2021

A Novel Three-LncRNA Signature Predicting Tumor Recurrence in Nonfunctioning Pituitary Adenomas.

Frontiers in genetics
2021

Pseudocapsular resection in elderly patients with non-functioning pituitary adenoma.

Clinical neurology and neurosurgery
2021

Deep learning-based thin-section MRI reconstruction improves tumour detection and delineation in pre- and post-treatment pituitary adenoma.

Scientific reports
2021

Machine-Learning Prediction of Postoperative Pituitary Hormonal Outcomes in Nonfunctioning Pituitary Adenomas: A Multicenter Study.

Frontiers in endocrinology
2021

Baseline MRI findings as predictors of hypopituitarism in patients with non-functioning pituitary adenomas.

Endocrine connections
2021

Cardiovascular risk profile in growth hormone-treated adults with craniopharyngioma compared to non-functioning pituitary adenoma: a national cohort study.

European journal of endocrinology
2021

Isolated Neuropsychiatric Features with Non-functioning Pituitary Adenoma: Association or Coincidence?

Journal of pediatric neurosciences
2021

Pseudo-Cushing's state in a patient with non-functioning pituitary adenoma.

BMJ case reports
2021

Stereotactic Radiosurgery and Hypofractionated Stereotactic Radiotherapy for Nonfunctioning Pituitary Adenoma.

Journal of neurological surgery. Part B, Skull base
2021

Safety of growth hormone (GH) treatment in GH deficient children and adults treated for cancer and non-malignant intracranial tumors-a review of research and clinical practice.

Pituitary
2022

Predictive factors of postoperative diabetes insipidus in 333 patients undergoing transsphenoidal surgery for non-functioning pituitary adenoma.

Pituitary
2024

The open sella technique for surgical treatment of pituitary macroadenomas: Safety and efficacy in a large clinical series.

British journal of neurosurgery
2021

Giant Recurrence Pituitary Adenoma After Three Times Transphenoidal Removal Surgery, One Craniotomy Procedure, and 30 Doses of External Radiotherapy.

Acta medica Indonesiana
2021

Sphenoid sinus mucosal thickening in patients with non-functioning pituitary adenoma.

International journal of clinical practice
2021

Pituitary Hormonal Status after Endoscopic Endonasal Transphenoidal Removal of Nonfunctioning Pituitary Adenoma: 5 years' Experience in a Single Center.

Asian journal of neurosurgery
2021

Pituitary disease and pregnancy.

Endocrinologia, diabetes y nutricion
2022

Safety of Endoscopic Transsphenoidal Pituitary Surgery during the COVID-19 Pandemic and Comparison to the Pre-Pandemic Era.

Journal of neurological surgery. Part B, Skull base
2021

Non-functioning pituitary adenomas and pregnancy: one-center experience and review of the literature.

Archives of endocrinology and metabolism
2021

Up-To-Date Magnetic Resonance Imaging Findings for the Diagnosis of Hypothalamic and Pituitary Tumors.

Yonago acta medica
2021

Early hormonal recovery following endoscopic transsphenoidal surgery for silent non-functioning pituitary adenomas with hormone dysfunction.

Journal of neuro-oncology
2021

Screening and Identification of Key Microenvironment-Related Genes in Non-functioning Pituitary Adenoma.

Frontiers in genetics
2021

Rapid resolution of a third nerve palsy from pituitary apoplexy.

BMJ case reports
2021

The outcome of TSHoma from a tertiary care institute in India.

Surgical neurology international
2021

Quality of Life and Sleep in Patients with Pituitary Adenoma in Relation to Tumor Type and Compression of the Optic Chiasm.

Journal of clinical medicine
2021

Role of pituitary stalk and gland radiological status on endocrine function and outcome after endoscopic transsphenoidal surgery for non-functioning pituitary adenomas.

Endocrine
2021

GH-induced LH hyporesponsiveness as a potential mechanism for hypogonadism in male patients with acromegaly.

Endocrine journal
2021

A comparative study of functioning and non-functioning pituitary adenomas.

Medicine
2021

Nomogram predictive model of post-operative recurrence in non-functioning pituitary adenoma.

Gland surgery
2021

Outcome Squares Integrating Efficacy and Safety, as Applied to Functioning Pituitary Adenoma Surgery.

The Journal of clinical endocrinology and metabolism
2021

Identifying critical protein-coding genes and long non-coding RNAs in non-functioning pituitary adenoma recurrence.

Oncology letters
2020

Clinical Parameters of Silent Corticotroph Adenomas With Positive and Negative Adrenocorticotropic Hormone Immunostaining: A Large Retrospective Single-Center Study of 105 Cases.

Frontiers in endocrinology
2021

Practice patterns in the management of recurrent and residual non-functioning pituitary adenomas: Results from a Canada-wide survey.

eNeurologicalSci
2020

Dome-Shaped Pituitary Enlargement in Primary Hypothyroidism: Avoiding Neurosurgical Interventions.

Journal of the ASEAN Federation of Endocrine Societies
2020

Identification of a TMEM127 variant in a patient with paraganglioma and acromegaly.

Endocrinology, diabetes & metabolism case reports
2020

ESE audit on management of Adult Growth Hormone Deficiency in clinical practice.

European journal of endocrinology
2020

Pseudoacromegaly Associated with Non-Functioning Pituitary Adenoma.

European journal of case reports in internal medicine
2021

Chromosomal and oxidative DNA damage in non-functioning pituitary adenomas.

Endokrynologia Polska
2021

Cephalocaudal tumor diameter is a predictor of diabetes insipidus after endoscopic transsphenoidal surgery for non-functioning pituitary adenoma.

Pituitary
2021

Chiasmapexy for secondary empty sella syndrome: diagnostic and therapeutic considerations.

Pituitary
2020

Characteristics and clinical outcomes in pituitary incidentalomas and non-incidental pituitary tumors treated with endoscopic transsphenoidal surgery.

Medicine
2021

Incidence, mortality, and cardiovascular diseases in pituitary adenoma in Korea: a nationwide population-based study.

Pituitary
2020

MRI radiomics for the prediction of recurrence in patients with clinically non-functioning pituitary macroadenomas.

Computers in biology and medicine
2020

The GALANT trial: study protocol of a randomised placebo-controlled trial in patients with a 68Ga -DOTATATE PET-positive, clinically non-functioning pituitary macroadenoma on the effect of lan reotide on t umour size.

BMJ open
2020

Full Remission of Long-Term Premenstrual Dysphoric Disorder-Like Symptoms Following Resection of a Pituitary Adenoma: Case Report.

The American journal of case reports
2020

The quality of life after transnasal microsurgical and endoscopic resection of nonfunctioning pituitary adenoma.

Advances in clinical and experimental medicine : official organ Wroclaw Medical University
2020

Health-related quality of life in patients with non-functioning pituitary adenoma: a special focus on hydrocortisone replacement dose.

Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation
2020

Cell proliferation, apoptosis, and angiogenesis in non-functional pituitary adenoma: association with tumor invasiveness.

Endocrine
2021

Association of PTP4A3 expression and tumour size in functioning pituitary adenoma: a descriptive study.

Journal of clinical pathology
2020

Current Status of Diagnosis and Management for Functioning Pituitary Tumors: Part I.

Neurology India
2020

Identification of a multidimensional transcriptome signature predicting tumor regrowth of clinically non‑functioning pituitary adenoma.

International journal of oncology
2020

Quality of care evaluation in non-functioning pituitary adenoma with chiasm compression: visual outcomes and timing of intervention clinical recommendations based on a systematic literature review and cohort study.

Pituitary
2019

NON-FUNCTIONAL PITUITARY TUMORS: A MISLEADING PRESENTATION OF AN INTRASELLAR PLASMACYTOMA.

Acta endocrinologica (Bucharest, Romania : 2005)
2020

The coexistence of recurrent pituitary adenoma and meningioma: case report.

Translational cancer research
2020

Comparative analysis of rhinologic outcomes in Cushing disease and non-functioning pituitary adenoma in patients submitted to endoscopic endonasal transsphenoidal surgery.

European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
2020

Content and system development of a digital patient-provider communication tool to support shared decision making in chronic health care: InvolveMe.

BMC medical informatics and decision making
2020

68Ga-DOTATATE PET imaging in clinically non-functioning pituitary macroadenomas.

European journal of hybrid imaging
2020

Integrated analysis of DNA methylation and mRNA expression profiles to identify key genes involved in the regrowth of clinically non-functioning pituitary adenoma.

Aging
2020

Cut-off values for sufficient cortisol response to low dose Short Synacthen Test after surgery for non-functioning pituitary adenoma.

Acta neurochirurgica
2021

Giant Non-Functioning Pituitary Adenoma: Clinical Characteristics and Therapeutic Outcomes.

Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association
2019

Identification of key genes in invasive clinically non-functioning pituitary adenoma by integrating analysis of DNA methylation and mRNA expression profiles.

Journal of translational medicine
2020

Preoperative growth hormone (GH) peak values during a GH releasing peptide-2 test reflect the severity of hypopituitarism and the postoperative recovery of GH secretion in patients with non-functioning pituitary adenomas.

Endocrine journal
2020

An aggressive functioning pituitary adenoma treated with peptide receptor radionuclide therapy.

European journal of nuclear medicine and molecular imaging
2020

Multimodal therapy in aggressive pituitary tumors.

Endocrinologia, diabetes y nutricion
2019

Postoperative expression of Cushing disease in a young male: metamorphosis of silent corticotroph adenoma?

Endocrinology, diabetes & metabolism case reports
2019

T5224, RSPO2 and AZD5363 are novel drugs against functional pituitary adenoma.

Aging
2019

Identification of CDK6 and RHOU in Serum Exosome as Biomarkers for the Invasiveness of Non-functioning Pituitary Adenoma.

Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih
2019

Functioning Pituitary Adenoma with Xanthogranulomatous Features: Review of Literature and Case Report.

Journal of neurological surgery. Part B, Skull base
2019

Cavernous sinus haemangioma with intrasellar extension mimicking non-functioning pituitary adenoma - A case report and review of literature.

Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology
2019

The burden of disease for pituitary patients.

Best practice & research. Clinical endocrinology & metabolism
2020

The benefit and risk of stereotactic radiosurgery for prolactinomas: an international multicenter cohort study.

Journal of neurosurgery
2019

Significance of Elevated HMGB1 Expression in Pituitary Apoplexy.

Anticancer research
2019

Endocrinological Outcome of Endoscopic Transsphenoidal Surgery for Functioning and Non-Functioning Pituitary Adenoma.

The Malaysian journal of medical sciences : MJMS
2023

Unexpected concomitant pituitary adenoma and suprasellar meningioma: a case report and review of the literature.

British journal of neurosurgery
2019

The pre- and postoperative illness trajectory in patients with pituitary tumours.

Endocrine connections
2019

Predicting the regrowth of clinically non-functioning pituitary adenoma with a statistical model.

Journal of translational medicine
2019

Non-functioning pituitary macroadenoma: surgical outcomes, tumor regrowth, and alterations in pituitary function-3-year experience from the Iranian Pituitary Tumor Registry.

Hormones (Athens, Greece)
2019

Identification of Important Invasion-Related Genes in Non-functional Pituitary Adenomas.

Journal of molecular neuroscience : MN
2019

Quality of Life but not Cognition is Impacted by Radiotherapy in Patients with Non-Functioning Pituitary Adenoma.

Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme
2019

Pre-operative MRI predictors of hormonal remission status post pituitary adenoma resection.

Clinical imaging
2019

Endocrinological Outcomes of Intraoperative MRI-Guided Endoscopic Transsphenoidal Surgery for Non-Functioning Pituitary Adenoma.

Turkish neurosurgery
2019

Incidence rate and risk factors of early repolarization in patients with growth hormone-secreting pituitary adenoma: a cohort study.

Therapeutics and clinical risk management
2019

Association of PTTG1 polymorphism rs1895320, rs2910200 and rs6882742 with non-functioning pituitary adenomas in Chinese Han population: a case-control study.

Metabolic brain disease
2018

Recurrence in silent corticotroph adenomas after primary treatment: A systematic review and meta-analysis.

The Journal of clinical endocrinology and metabolism
2019

A two‑circRNA signature predicts tumour recurrence in clinical non‑functioning pituitary adenoma.

Oncology reports
2019

Genome-wide identification of lncRNAs and mRNAs differentially expressed in non-functioning pituitary adenoma and construction of an lncRNA-mRNA co-expression network.

Biology open
2023

Spindle cell oncocytoma of the neurohypophysis with metastasis to the sphenoparietal sinus and immunohistochemical negativity for S100 and epithelial membrane antigen (EMA).

British journal of neurosurgery
2019

Autoimmune thyroid diseases are more common in patients with prolactinomas: a retrospective case-control study in an Italian cohort.

Journal of endocrinological investigation
2018

Comorbidities in patients with non-functioning pituitary adenoma: influence of long-term growth hormone replacement.

European journal of endocrinology
2018

FGFR2 gene polymorphism rs2981582 is associated with non-functioning pituitary adenomas in Chinese Han population: a case-control study.

Bioscience reports
2018

Spectrum of Pituitary disorders: A retrospective study from Basrah, Iraq.

F1000Research

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Adenoma hipofisário funcional.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Adenoma hipofisário funcional

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. The clinical value of [18F]-fluoro-ethyl-L-tyrosine PET ([18F]FET-PET) correlated with MRI in patients with functioning pituitary adenomas: an observational cohort study.
    Pituitary· 2026· PMID 41793555mais citado
  2. Oridonin regulates pituitary-derived folliculostellate cells apoptosis via the p38 MAPK/p53 signalling pathway.
    European journal of pharmacology· 2026· PMID 41724459mais citado
  3. Sex-related differences in healthcare utilization and costs among patients with pituitary adenomas.
    Pituitary· 2026· PMID 41653359mais citado
  4. Decoy Lesion in Functional Multiple Pituitary Adenomas: Literature Review and Illustrative Cases on Diagnostic Pitfalls and Surgical Strategies.
    World neurosurgery· 2026· PMID 41651066mais citado
  5. Cavernous Sinus Medial Wall Resection: A Retrospective Single-Institution Study on Outcomes in Functional Pituitary Adenomas.
    Operative neurosurgery (Hagerstown, Md.)· 2026· PMID 41636530mais citado
  6. Hypogonadotropic Hypogonadism Before and After Transsphenoidal Surgery for Non-Functioning Pituitary Adenoma.
    Clin Endocrinol (Oxf)· 2026· PMID 41940466recente
  7. The impact of a non-functioning pituitary adenoma on life - A qualitative study of patients' experiences.
    PLoS One· 2026· PMID 41915654recente

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:314753(Orphanet)
  2. MONDO:0003429(MONDO)
  3. GARD:21389(GARD (NIH))
  4. Variantes catalogadas(ClinVar)
  5. Busca completa no PubMed(PubMed)
  6. Q18556775(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Adenoma hipofisário funcional
Compêndio · Raras BR

Adenoma hipofisário funcional

ORPHA:314753 · MONDO:0003429
Ensaios
1 ativos
MedGen
UMLS
C0854486
EuropePMC
Wikidata
Papers 10a
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades